Molecular and genetic predisposing factors of comorbidity of fatty liver disease and diseases of the colon

Bibliography:
1. Buyeverova YeL, Drapkina OM, Ivashkin VT. Non-alcoholic fatty liver disease at atherogenic dyslipidemia: therapeutic options of internist. Russian medical news 2014; XIX (3): 28-36
2. Bueverov SA, Bogomolov РО. Nonalcoholic fatty liver disease: substantiation of pathogenetic therapy. Clinical prospects of gastroenterology, hepatology 2009; 1: 3-9
3. Balukova EV, Assumption YP. Nonalcoholic fatty liver disease and metabolic syndrome. Poliklinika. Spetsvypusk: Gastroenterologiya 2014; 1: 45-48
4. Silva J, Meyenn F, Howell J. Regulation of adaptive behaviour during fasting by hypothalamic Foxa2. Nature 2009; 462: 646-650
5. Moya M, Benet M, Guzman C, et al. Foxal reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver. PLOS One 2012; 7 (1): 1-17
6. Verbovoy AF, Solomonov ES, Pashentseva AV. Leptin, resistin and omentin in patients with impaired glucose tolerance and type 2 diabetes. University proceedings. Volga region 2012; 3 (23): 52-59
7. Starodubova AV. Overweight and obesity as risk factors for non-alcoholic fatty liver disease. Archive of internal medicine 2014; 5 (19): 10-20
8. Titov VN, Ivanova KV, Malyshev PP, et al. The unity of pathogenesis of insulin resistance syndrome and non-alcoholic fatty disease of liver: The metabolic disorder of fatty acids and triglycerides. Klinicheskaya laboratornaya diagnostika 2012; 11: 3-12
9. SchekotovaAP. State of epithelium in chronic diffusive liver diseases. Perm medical journal 2009; 26 (2): 78-82
10. Ferre Р, Fouteile F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010; 12 (2): 83-92
11. Kosobyan EP, Smirnova OM. Current concepts of the pathogenesis of non-alcoholic fatty liver disease. Diabetes mellitus 2010; 1: 55-64
12. Ivashkin VT Nuclear receptors and liver disease. Russian Journal of gastroenterology, hepatology, coloproctology 2010; 20 (3):4-8
13. Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother 2014; 15 (4): 493-503
14. Romantsova Tl, Dedov II, Kuznetsov IS. Endocannabinoid system: structure and potential in regulating weight and metabolism. Obesity and Metabolism 2006; 4: 2-11
15. Dongiovanni Р, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism Clinical and Experimental 2015; X:3-12
16. Zvenigorodskaya LA. Nonalcoholic fatty liver disease: evolution of ideas. Effective pharmacotherapy. Gastroenterology 2015; 2: 16-22
17. Butorova LI. The non-alcoholic fatty liver disease as a manifestation of the metabolic syndrome: epidemiology, pathogenesis, clinical manifestations, principles of diagnosis, modern treatment options: A Guide for Physicians. M.: Forte Print, 2012; 52 p.
18. Dai X, Wang В. Role of gut barrier function in the pathogenesis of nonalcoholic fatty liver disease. Gastroenterology Research and Practice 2015: 1-6
19. Maevskay YeA, Kucheryavy YuA, Maev IV Nonalcoholic fatty liver disease and chronic constipation: casual of obvious association in practice of the gastroenterologist? Clinical prospects of gastroenterology, hepatology 2015; 1: 27-36
20. Anisimova EV, Kozlova IV, Volkov SV, et al. Pathology of digestive organs at adiposity (review). Saratov Journal of Medical Scientific Research 2011; 7 (4): 851-856
21. Scalera A, Minno М, Tarantino G. What does irritable bowel syndrome share with non-alcoholic fatty liver disease? World J Gastroenterol 2013 September 7; 19 (33): 5402-5420
22. Kozlova IV, Osadchuk MA, Kvetnoy IM. Changes of APUD system of the colon as a risk factor for colorectal cancer. Clinical Medicine 1999; 8: 26-29
23. Kozlova IV Osadchuk MA, Kvetnoy IM, et al. Melatonin and serotonin in inflammatory diseases of the colon and colorectal cancer. Clinical Medicine 2000; 78 (6): 32-35
24. Uslu S, Ozcelik E. Metabolic syndrome and colorectal cancer: a review. The Journal of Medical Sciences Report and Research 2013; 1:1-9
25. Armillaria TG. Cancer and the metabolic syndrome: a common ground. World of Science, Culture, Education 2010; 5 (24): 271-274
26. Michaud D, Giovannucci E, Willett W. Physical activity obesity, height and the risk of pancreatic cancer. JAMA 2001; 286 (8): 921-929
27. Wong VW, Wong GL, Tsang SW, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011; 60 (6): 829-36
28. Stadlmayr A, Aigner E, Steger B, et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med 2011; 270 (1): 41-9
29. Huang KW, Leu HB, Wang YJ, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis 2013; 15 (7): 830-5
30. Ding W, Fan J, QinJ. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis. Int J Clin Exp Med 2015; 8 (1): 322-33
31. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578
32. Nikitin YuP, Openko TG, Simonova Gl. Metabolic syndrome and its components as possible modified risk factors (Literature review). Siberian journal of oncology 2012; 2 (50): 68-72
33. Khalili Н, Chan A. Is Diabetes a Risk Factor for Colorectal Cancer? Digestive Diseases and Sciences 2012; 57: 1427-1429
34. Deng L, Gui Z, Zhao L, et al. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci 2012; 57 (6): 1576-85
35. Chang CK, Ulrich CM. Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 2003; 46: 595-607
36. Shaposhnikov AV. Colorectal cancer: Carcinogenesis and onkoprevention: A guide for physicians. Moscow: Forte Print; 2015; 160 p.
37. Pelicano Н, Xu RH, Du М, et al. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 2006; 175: 913-923
38. Nikolaev AA, Gerstein ES, Korotkov EA, et al. Colorectal cancer and IGF. Oncological coloproctology 2013; 2: 11-14
39. Gionleme О, Diamantidis MD, Katsaros MG. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. W.J. G. 2011; 17 (4): 444-448 40. Shirakami Y, et al. Chemoprevention of colorectal cancer with obesity. World J Gastroenterology 2014; 20 (27): 8939-8946.